NASDAQ:SEEL - Seelos Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.00
  • Forecasted Upside: 361.54 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.60
▼ -0.06 (-2.26%)
1 month | 3 months | 12 months
Get New Seelos Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SEEL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SEEL

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$12.00
▲ +361.54% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Seelos Therapeutics in the last 3 months. The average price target is $12.00, with a high forecast of $12.00 and a low forecast of $12.00. The average price target represents a 361.54% upside from the last price of $2.60.
Buy
The current consensus among 1 investment analysts is to buy stock in Seelos Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/14/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/13/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/12/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/10/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/8/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/7/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/5/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/7/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/28/2020Roth CapitalReiterated RatingBuy$12.00High
i
Rating by J. Aschoff at Roth Capital
6/23/2020Roth CapitalBoost Price TargetBuy$8.00 ➝ $12.00High
i
Rating by J. Aschoff at Roth Capital
11/18/2019HC WainwrightBoost Price TargetBuy$2.00 ➝ $4.00High
i
11/14/2019BenchmarkInitiated CoverageBuy$4.00High
i
8/2/2019Roth CapitalSet Price TargetBuy$8.00Low
i
Rating by Y. Rahimi at Roth Capital
5/14/2019Roth CapitalInitiated CoverageBuy ➝ Buy$8.00High
i
Rating by Y. Rahimi at Roth Capital
5/10/2019HC WainwrightInitiated CoverageBuy$4.00High
i
Rating by V. Bernardino at HC Wainwright
(Data available from 3/8/2016 forward)
Seelos Therapeutics logo
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorder and post-traumatic stress disorder; SLS-005, a protein stabilizer for the treatment of Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.
Read More

Today's Range

Now: $2.60
$2.17
$2.79

50 Day Range

MA: $2.89
$1.44
$4.03

52 Week Range

Now: $2.60
$0.42
$4.44

Volume

3,250,500 shs

Average Volume

3,677,023 shs

Market Capitalization

$138.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.36

Frequently Asked Questions

What sell-side analysts currently cover shares of Seelos Therapeutics?

The following sell-side analysts have issued stock ratings on Seelos Therapeutics in the last year: Roth Capital, and Zacks Investment Research.
View the latest analyst ratings for SEEL.

What is the current price target for Seelos Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Seelos Therapeutics in the last year. Their average twelve-month price target is $12.00, suggesting a possible upside of 361.5%. Roth Capital has the highest price target set, predicting SEEL will reach $12.00 in the next twelve months. Roth Capital has the lowest price target set, forecasting a price of $12.00 for Seelos Therapeutics in the next year.
View the latest price targets for SEEL.

What is the current consensus analyst rating for Seelos Therapeutics?

Seelos Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SEEL will outperform the market and that investors should add to their positions of Seelos Therapeutics.
View the latest ratings for SEEL.

What other companies compete with Seelos Therapeutics?

How do I contact Seelos Therapeutics' investor relations team?

Seelos Therapeutics' physical mailing address is 300 PARK AVENUE 12TH FLOOR, NEW YORK NY, 10022. The company's listed phone number is 646-293-2100 and its investor relations email address is [email protected] The official website for Seelos Therapeutics is www.seelostherapeutics.com.